Biomea Fusion shares are trading lower by 62.7% during Friday's session. The company received notice from the FDA that Its trials of BMF-219 have been placed on clinical hold.
- Results from a randomized, placebo-controlled study of TRIKAFTA® in people with cystic fibrosis with rare, non-F508del CFTR mutations showed statistically significant and clinically meaningful improvements in the
KARL STORZ Endoscopy-America has agreed to acquire Asensus Surgical for $0.35 per share, representing a 67% premium. This acquisition will bolster KARL STORZ's robotic surgical market presence.